Shares of Novo Nordisk increased by 1.3% after U.S. President Joe Biden proposed expanding coverage of anti-obesity drugs for Medicare and Medicaid recipients. Novo Nordisk welcomed the move, stating it would benefit patients and could take effect in 2026.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing